MRSN vs SNPS · rev $40.5M vs P/E 63, rev $7.16B
Mersana Therapeutics Inc (MRSN) versus Synopsys Inc (SNPS) — a side-by-side from cached financials, not a winner call.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
Synopsys Inc (SNPS) is a software - infrastructure company listed on US. It is led by Sassine Ghazi.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
Latest reported SNPS revenue for 2026-07-31 was $7.16B. Net income was $627.9M. Revenue was up 52.9% from 2026-04-30 to 2026-07-31. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
MRSN currently screens at market cap $145.4M. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
Not investment advice. Open the MRSN and SNPS stock pages for the full models.
Not investment advice.